CytRx (NASDAQ:CYTR) will be releasing its earnings data before the market opens on Friday, November 2nd. Analysts expect CytRx to post earnings of ($0.09) per share for the quarter.
CytRx (NASDAQ:CYTR) last announced its quarterly earnings data on Monday, August 6th. The biotechnology company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.08. On average, analysts expect CytRx to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of CytRx stock traded down $0.03 during trading on Tuesday, hitting $0.70. 30,983 shares of the stock traded hands, compared to its average volume of 168,701. The firm has a market capitalization of $24.72 million, a PE ratio of -0.46 and a beta of 1.74. CytRx has a 52 week low of $0.65 and a 52 week high of $2.59.
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies.
Read More: Asset Allocation
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.